Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
Norgard RJ, Budhani P, O'Brien SA, Xia Y, Egan JN, Flynn B, Tagore JR, Seco J, Peet GW, Mikucka A, Wasti R, Chan LC, Hinkel M, Martinez-Morilla S, Pignatelli J, Trapani F, Corse E, Feng D, Kostyrko K, Hofmann MH, Liu K, Kashyap AS. Norgard RJ, et al. Among authors: hofmann mh. Cancer Res Commun. 2024 Jun 21;4(6):1548-1560. doi: 10.1158/2767-9764.CRC-24-0172. Cancer Res Commun. 2024. PMID: 38727236 Free PMC article.
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, Wunberg T, Zoephel A, Fu SC, Teh JL, Böttcher J, Pototschnig N, Schachinger F, Schipany K, Lieb S, Vellano CP, O'Connell JC, Mendes RL, Moll J, Petronczki M, Heffernan TP, Pearson M, McConnell DB, Kraut N. Hofmann MH, et al. Cancer Discov. 2021 Jan;11(1):142-157. doi: 10.1158/2159-8290.CD-20-0142. Epub 2020 Aug 19. Cancer Discov. 2021. PMID: 32816843 Free PMC article.
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann I, Baum A, Hofmann MH, Trapani F, Reichel-Voda C, Ehrensperger D, Aichinger M, Ebner F, Budano N, Schweifer N, Sykora M, Depla E, Boucneau J, Gschwind A, Kraut N, Hilberg F, Künkele KP. Hofmann I, et al. Among authors: hofmann mh. J Pharmacol Exp Ther. 2023 Mar;384(3):331-342. doi: 10.1124/jpet.122.001255. Epub 2022 Oct 14. J Pharmacol Exp Ther. 2023. PMID: 36241203
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.
Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow CA, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Lieb S, Jeschko A, Machado AA, Marszalek ED, Mahendra M, Jaeger PA, Sorokin A, Strauss S, Trapani F, Kopetz S, Vellano CP, Petronczki M, Kraut N, Heffernan TP, Marszalek JR, Pearson M, Waizenegger I, Hofmann MH. Thatikonda V, et al. Among authors: hofmann mh. bioRxiv [Preprint]. 2023 Jan 23:2023.01.23.525210. doi: 10.1101/2023.01.23.525210. bioRxiv. 2023. Update in: Nat Cancer. 2024 Sep;5(9):1352-1370. doi: 10.1038/s43018-024-00800-6 PMID: 36747713 Free PMC article. Updated. Preprint.
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.
Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, Alpar D, Arnhof H, Bergner O, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Hinkel M, Lieb S, Jeschko A, Machado AA, Madensky T, Marszalek ED, Mahendra M, Melo-Zainzinger G, Molkentine JM, Jaeger PA, Peng DH, Schenk RL, Sorokin A, Strauss S, Trapani F, Kopetz S, Vellano CP, Petronczki M, Kraut N, Heffernan TP, Marszalek JR, Pearson M, Waizenegger IC, Hofmann MH. Thatikonda V, et al. Among authors: hofmann mh. Nat Cancer. 2024 Sep;5(9):1352-1370. doi: 10.1038/s43018-024-00800-6. Epub 2024 Aug 5. Nat Cancer. 2024. PMID: 39103541 Free PMC article.
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma.
Marasco M, Kumar D, Seale T, Borrego SG, Kaplun E, Aricescu I, Cole S, Qeriqi B, Qiu J, Chen X, Bahr A, Fidele D, Hofmann MH, Gerlach D, Savarese F, Merghoub T, Wolchok JD, Yao Z, de Stanchina E, Solit D, Misale S, Rosen N. Marasco M, et al. Among authors: hofmann mh. Cell Rep Med. 2024 Nov 19;5(11):101818. doi: 10.1016/j.xcrm.2024.101818. Epub 2024 Nov 1. Cell Rep Med. 2024. PMID: 39488215 Free PMC article.
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.
Sanderson MP, Hofmann MH, Garin-Chesa P, Schweifer N, Wernitznig A, Fischer S, Jeschko A, Meyer R, Moll J, Pecina T, Arnhof H, Weyer-Czernilofsky U, Zahn SK, Adolf GR, Kraut N. Sanderson MP, et al. Among authors: hofmann mh. Mol Cancer Ther. 2017 Oct;16(10):2223-2233. doi: 10.1158/1535-7163.MCT-17-0336. Epub 2017 Jul 20. Mol Cancer Ther. 2017. PMID: 28729397
76 results